03/11/2026
Researchers at the Hebrew University of Jerusalem have uncovered evidence that CBD & CBG, two non-intoxicating cannabis compounds could offer a fresh path forward for treating metabolic dysfunction-associated steatotic liver disease (MASLD) — the most prevalent chronic liver disorder on the planet.
Non-alcoholic fatty liver disease affects roughly a quarter of the world's population. It's becoming one of the most common chronic health conditions on Earth, and there are very few effective treatments.
Fatty liver disease affects millions and quietly erodes health by disrupting how the liver stores and uses energy. New research has turned attention to two cannabis-derived compounds, CBD and CBG, because they appear to help liver cells refuel and clear out damaged components. That matters because a liver with healthier energy balance and functioning cleanup.
Israeli scientists have discovered that the non-intoxicating cannabis compounds CBD and CBG improve liver health through two cellular mechanisms: boosting energy reserves and restoring cellular cleaning. The research, published in the British Journal of Pharmacology, paves the way for the first treatment for non-alcoholic fatty liver disease.
In a study published just days ago (March 5, 2026) in the British Journal of Pharmacology, researchers from the Hebrew University of Jerusalem revealed a new mechanism for treating fatty liver disease. They discovered that the non-psychoactive compounds CBD and CBG work together to perform "metabolic remodeling." Specifically, they found these cannabinoids restore the activity of cathepsins—enzymes that act as a cellular "cleaning crew" inside lysosomes. By jumpstarting these cleanup systems, the treatment significantly slashed liver fat and improved blood sugar control, offering a 2026 plant-based alternative for the world's most common chronic liver disorder.
These findings identify a novel, endocannabinoid system-independent mechanism by which CBD and CBG enhance hepatic energy buffering and lysosomal function, contributing to improved liver lipid handling and supporting phytocannabinoids as promising MASLD therapeutics.
These statements have not been evaluated by the FDA. For educational purposes only. Not medical advice.
Cannabis compounds CBD and CBG may help reverse fatty liver disease, study finds
https://www.sciencedaily.com/releases/2026/03/260306145616.htm
Cannabidiol and cannabigerol ameliorate steatotic liver disease via phosphocreatine buffering and lysosomal restoration
https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.70387
Shop our CBD & CBG products at H**pMazeMN.com
*We do not claim to treat, diagnose, or cure illness. These statements have not been evaluated by the FDA. For educational purposes only. Not medical advice.
